Key Highlights
- Net Revenue was about USD 635,000 in the third quarter of 2026, up 247% from about USD 183,000 a year earlier, as Demand grew for QUELIMMUNE, its therapy for ultra-rare pediatric kidney injury.
- Net loss was about USD 4.5 million, or USD 1.03 per share, against about USD 3.5 million, or USD 1.30, a year earlier, with operating expenses rising to USD 5.2 million from USD 3.7 million.
- Cash was about USD 4 million on September 30, 2026, down from about USD 12 million at December 31, 2025, and that excludes USD 3.3 million of gross Warrant exercise proceeds received in October.
- The adult NEUTRALIZE-AKI trial has enrolled 251 of 339 patients, and management now expects enrollment to finish by midyear 2027, later than it had guided before.
Pediatric Demand Lifts Net Revenue 247%
SeaStar Medical (NASDAQ:ICU) discussed its third-quarter 2026 results on a call held November 11, 2026. The chief financial officer said net revenue was approximately USD 635,000, up 247% from approximately USD 183,000, with Gross Profit above 90% of revenue. Management said nine-month QUELIMMUNE net revenue more than doubled to USD 1.7 million, which puts the company on course to exceed its USD 2 million full-year guidance, though it set no new number. Twenty of the top 50 pediatric medical centers are customers, and 10 were added this year. A question on the call noted revenue was little changed from the second quarter; management pointed to the year-ago comparison and to the ultra-rare patient pool, since use depends on each hospital's eligible caseload.
Wider Loss and Thin Cash Shape the Funding Picture
Operating expenses rose to USD 5.2 million from USD 3.7 million, about 41% higher by simple calculation, mainly on Research and Development tied to NEUTRALIZE-AKI, while general and administrative spending fell on lower personnel, legal and audit costs. Net loss was about USD 4.5 million, or USD 1.03 per share on roughly 4.4 million weighted shares, against USD 1.30 on roughly 2.7 million a year earlier. The per-share loss narrowed even as the dollar loss grew because the share count rose. Cash of about USD 4 million leaves a modest cushion for a company whose only product serves a very small patient group, so how it is funded is worth watching.
Trial Timeline Slips as Sepsis Designation Arrives
The adult NEUTRALIZE-AKI study has enrolled 251 of 339 patients, about 75%. Management said strict inclusion criteria slow recruitment and moved its expected completion of enrollment to midyear 2027, with the final premarket approval module due about nine months after that. It said the timeline could shorten as new sites open. The FDA also granted Breakthrough Device Designation for adult sepsis, the seventh for the therapy, and management said a prespecified analysis in the trial covers sepsis patients. In the SAVE registry, 65% of 50 treated children survived to day 90 against 47% in a comparison cohort, with a p-value of 0.043.
Where Things Stand
SeaStar Medical (NASDAQ:ICU) grew revenue 247% by getting its pediatric therapy into more hospitals, but the base is tiny and cash of about USD 4 million is the pressure point. The gain came from QUELIMMUNE, while the larger adult opportunity now waits on a trial whose enrollment finish moved to midyear 2027. The next markers are the 10-Q, which management said would be filed within 24 hours of the call, further premarket approval modules, new hospital customers and how the company funds operations beyond the October warrant proceeds.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...